Research programme: anti-thrombotic compounds - Ception Therapeutics
Latest Information Update: 27 May 2010
At a glance
- Originator Ception Therapeutics
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Jan 2007 Preclinical trials in Thrombosis in USA (unspecified route)